Switch to:
Repros Therapeutics Inc (NAS:RPRX)
Piotroski F-Score
3 (As of Today)

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Repros Therapeutics Inc has an F-score of 3 indicating the company's financial situation is typical for a stable company.

RPRX' s 10-Year Piotroski F-Score Range
Min: 1   Max: 7
Current: 3

1
7

During the past 13 years, the highest Piotroski F-Score of Repros Therapeutics Inc was 7. The lowest was 1. And the median was 4.


Definition

How is the Piotroski F-Score calculated?

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

This Year (Jun14) TTM:Last Year (Jun13) TTM:
Net Income was -5.998 + -7.142 + -8.549 + -8.704 = $-30.39 Mil.
Cash Flow from Operations was -5.614 + -5.985 + -7.614 + -7.159 = $-26.37 Mil.
Revenue was 0.003 + 0.003 + 0.002 + 0.002 = $0.01 Mil.
Gross Profit was 0.003 + 0.003 + 0.002 + 0.002 = $0.01 Mil.
Average Total Assets from the begining of this year (Jun13)
to the end of this year (Jun14) was
(90.64 + 84.842 + 78.977 + 71.809 + 64.28) / 5 = $78.11 Mil.
Total Assets was $64.28 Mil.
Long-Term Debt was $0.00 Mil.
Total Current Assets was $61.04 Mil.
Total Current Liabilities was $4.09 Mil.
Net Income was -4.583 + -8.044 + -7.374 + -7.207 = $-27.21 Mil.

Revenue was 0.001 + 0.002 + 0.001 + 0.001 = $0.01 Mil.
Gross Profit was 0.001 + 0.002 + 0.001 + 0.001 = $0.01 Mil.
Average Total Assets from the begining of last year (Jun12)
to the end of last year (Jun13) was
(11.948 + 32.032 + 26.832 + 19.915 + 90.64) / 5 = $36.27 Mil.
Total Assets was $90.64 Mil.
Long-Term Debt was $0.00 Mil.
Total Current Assets was $88.00 Mil.
Total Current Liabilities was $3.94 Mil.

Profitability

Q1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by average total assets throughout the year.

Score 1 if positive, 0 if negative.

Repros Therapeutics Inc's current net income (ttm) was -30.39. ==> Negative ==> Score 0.

Q2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by average total assets throughout the year.

Score 1 if positive, 0 if negative.

Repros Therapeutics Inc's current cash flow from operations (ttm) was -26.37. ==> Negative ==> Score 0.

Q3. Change in Return on Assets

Compare this year’s return on assets (1) to last year’s return on assets.

Score 1 if it’s higher, 0 if it’s lower.

ROA (This Year)=Net Income (TTM)/Average Total Assets from Jun13 to Jun14
=-30.393/78.1096
=-0.3891071

ROA (Last Year)=Net Income (TTM)/Average Total Assets from Jun12 to Jun13
=-27.208/36.2734
=-0.75008133

Repros Therapeutics Inc's return on assets of this year was -0.3891071. Repros Therapeutics Inc's return on assets of last year was -0.75008133. ==> This year is higher. ==> Score 1.

Q4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA =< ROA.

Repros Therapeutics Inc's current net income (ttm) was -30.39. Repros Therapeutics Inc's current cash flow from operations (ttm) was -26.37. ==> -26.37 > -30.39 ==> CFROA > ROA ==> Score 1.

Funding

Q5. Change in Gearing or Leverage

Compare this year’s gearing (long-term debt divided by total assets) to last year’s gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun14)=Long-Term Debt/Total Assets
=0/64.28
=0

Gearing (Last Year: Jun13)=Long-Term Debt/Total Assets
=0/90.64
=0

Repros Therapeutics Inc's gearing of this year was 0. Repros Therapeutics Inc's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Q6. Change in Working Capital (Liquidity)

Compare this year’s current ratio (current assets divided by current liabilities) to last year’s current ratio.

Score 1 if this year'’s current ratio is higher, 0 if it’s lower

Current Ratio (This Year: Jun14)=Total Current Assets/Total Current Liabilities
=61.036/4.085
=14.94149327

Current Ratio (Last Year: Jun13)=Total Current Assets/Total Current Liabilities
=88.001/3.938
=22.34662265

Repros Therapeutics Inc's current ratio of this year was 14.94149327. Repros Therapeutics Inc's current ratio of last year was 22.34662265. ==> Last year's current ratio is higher ==> Score 0.

Q7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Repros Therapeutics Inc's number of shares in issue this year was 23.1. Repros Therapeutics Inc's number of shares in issue last year was 19. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Q8. Change in Gross Margin

Compare this year’s gross margin (gross profit divided by sales) to last year’s.

Score 1 if this year’s gross margin is higher, 0 if it’s lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.01/0.01
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.005/0.005
=1

Repros Therapeutics Inc's gross margin of this year was 1. Repros Therapeutics Inc's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Q9. Change in asset turnover

Compare this year’s asset turnover (total sales for the year divided by average total assets throughout the year) to last year’s asset turnover ratio.

Score 1 if this year’s asset turnover ratio is higher, 0 if it’s lower

Asset Turnover (This Year)=Revenue (TTM)/Average Total Assets from Jun13 to Jun14
=0.01/78.1096
=0.00012803

Asset Turnover (Last Year)=Revenue (TTM)/Average Total Assets from Jun12 to Jun13
=0.005/36.2734
=0.00013784

Repros Therapeutics Inc's asset turnover of this year was 0.00012803. Repros Therapeutics Inc's asset turnover of last year was 0.00013784. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score=Q1+Q2+Q3+Q4+Q5+Q6+Q7+Q8+Q9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 8 or 9

Bad or low score = 0 or 1

Repros Therapeutics Inc has an F-score of 3 indicating the company's financial situation is typical for a stable company.


Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Related Terms

Net Income, Cash Flow from Operations, Revenue, Gross Profit, Total Assets, Long-Term Debt, Total Current Assets, Total Current Liabilities, Altman Z-Score, Beneish M-Score


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Repros Therapeutics Inc Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Q1 0000000000
Q2 0000000000
Q3 0011001000
Q4 0010110111
Q5 1111111111
Q6 0101001111
Q7 1000000000
Q8 0000000000
Q9 0011010011
F-score 2244233344

Repros Therapeutics Inc Quarterly Data

Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14
Q1 0000000000
Q2 0000000000
Q3 0011111111
Q4 1111111111
Q5 1111111111
Q6 1111011110
Q7 0000000000
Q8 0000000000
Q9 0000111000
F-score 3344455443
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK